Is CRISPR Therapeutics Stock a Buy?
There's a lot of hype surrounding gene-editing technology, and considering its potential implications, that's no surprise. The ability to treat previously incurable genetic disorders could save the lives of hundreds of thousands, if not millions, of people around the world.
CRISPR Therapeutics (NASDAQ: CRSP) is one of the big players in this relatively young sector, having created a widely used genome-editing tool called CRISPR/Cas9. However, the excitement surrounding the gene-editing sector has taken a backseat to the ongoing COVID-19 pandemic. With markets around the world reporting significant losses as stock prices continue to fall over the past month, CRISPR's stock has followed suit.
Does that mean now's a good time to buy shares of this gene-editing biotech company? Let's find out.
Source Fool.com
